NDAORALSYRUP
Approved
Mar 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PERIACTIN (cyproheptadine hydrochloride) by Merck & Co. is clinical pharmacology cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. First approved in 1962.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERIACTIN (cyproheptadine HCl) is an oral syrup formulation approved in 1962 that acts as a serotonin and histamine antagonist with anticholinergic and sedative properties. It competes for receptor sites to block serotonin and histamine effects. The drug is indicated for allergic conditions and has been used off-label for appetite stimulation and serotonin syndrome management.
LOE Approaching
Legacy product with LOE approaching and moderate competitive pressure (30) indicating a mature, declining franchise with minimal team expansion likely.
Mechanism of Action
CLINICAL PHARMACOLOGY Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites. Pharmacokinetics and Metabolism After a single 4 mg oral…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PERIACTIN at LOE approaching offers limited upside; career value lies in managing mature asset decline, generic transition strategy, and cost optimization rather than launch or expansion. Roles focus on defending market share and ensuring profitable exit.
Worked on PERIACTIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.